Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer.

Bing FengFangyuan ZhouWenchao LuDangge WangTingting WangCheng LuoHao WangYaping LiHaijun Yu
Published in: Biomaterials science (2018)
A phospholipid-mimic oxaliplatin prodrug (Oxalipid) was synthesized, which could self-assemble into a liposomal nanostructure with a drug loading ratio as high as 27 wt%. Compared to free oxaliplatin, the resulting Oxalipid liposome displayed elongated blood circulation, increased tumor accumulation and improved anticancer efficacy against the metastatic triple negative breast cancer (TNBC).